Home pageALNOV • EPA
add
Novacyt
Chiusura precedente
0,67 €
Intervallo giornaliero
0,66 € - 0,69 €
Intervallo annuale
0,45 € - 1,59 €
Cap di mercato
47,90 Mln EUR
Volume medio
458.667,00
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
EPA
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
| (GBP) | giu 2024info | Variazione Y/Y |
|---|---|---|
Entrate | 5,16 Mln | 209,13% |
Spese di gestione | 7,92 Mln | 92,89% |
Utile netto | -8,85 Mln | -112,01% |
Margine di profitto netto | -171,47 | 31,41% |
Utili per azione | — | — |
EBITDA | -12,02 Mln | -324,07% |
Aliquota fiscale effettiva | 1,22% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (GBP) | giu 2024info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 32,95 Mln | -59,69% |
Totale attivo | 99,40 Mln | -24,78% |
Totale passivo | 28,99 Mln | 16,70% |
Patrimonio netto totale | 70,41 Mln | — |
Azioni in circolazione | 70,63 Mln | — |
Prezzo/valore contabile | 0,67 | — |
Redditività dell'attivo | -36,30% | — |
Rendimento sul capitale | -43,18% | — |
Flusso di cassa
Flusso di cassa netto
| (GBP) | giu 2024info | Variazione Y/Y |
|---|---|---|
Utile netto | -8,85 Mln | -112,01% |
Liquidità di esercizio | -4,54 Mln | -59,67% |
Contanti da investimenti | -566.500,00 | -212,18% |
Contanti da finanziamenti | -430.500,00 | -61,24% |
Flusso di cassa netto | -5,56 Mln | -112,16% |
Flusso di cassa libero | -17,73 Mln | -943,16% |
Informazioni
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Fondazione
2006
Sito web
Dipendenti
240
